查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1587831

中樞神經系統治療市場規模、佔有率和趨勢分析報告：按疾病、藥物類別、分銷管道、地區、細分市場預測，2025-2030

Central Nervous System Therapeutics Market Size, Share & Trends Analysis Report By Disease, By Drug Class (Anticonvulsants, CNS Stimulants), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

中樞神經系統治療市場的成長與趨勢：

根據Grand View Research, Inc.最新報告，預計到2030年，全球中樞神經系統藥物市場規模將達到2.546億美元，2025年至2030年複合年成長率為10.4%。

在預測期內，大量未滿足的醫療需求和政府減輕疾病負擔的措施正在推動中樞神經系統（CNS）治療市場的發展。據世界衛生組織稱，憂鬱症和焦慮症每年對全球經濟造成超過 1 兆美元的損失，預計到 2030 年，全球心理健康病例的增加將導致經濟損失增加 16 兆美元。

該市場未來具有強勁的成長機會，主要企業正在採取各種行銷策略來鞏固自己的地位，包括新產品開拓、合作夥伴關係、地理擴張、併購和新產品核可。 2020年2月，百健（Biogen）宣布投資 Sangamo 的鋅指平台，用於開發阿茲海默症和其他神經系統疾病的治療方法。同樣，該公司與 Ionis Pharmaceuticals 達成協議，開發可應用於多種神經系統疾病的候選藥物。

百健 (Biogen)、H. Lundbeck A/S、禮來公司 (Eli Lilly and Company) 等領先製藥公司推出的強大研發線產品預計將在預測期內加速市場成長。其他製藥公司也積極開發新治療方法，並投入大量資金開發治療中樞神經系統疾病的有效療法。

許多處於後期開發的藥物用於治療神經退化性疾病，例如阿茲海默症、多發性硬化症、帕金森氏症和肌萎縮側索硬化症。 aducanumab、brexpiprozole、evobrutinib 和 solanezumab 等候選藥物可能在未來五到八年內商業化，用於治療各種神經退化性疾病適應症。除了神經退化性疾病外，偏頭痛、思覺失調症和癲癇是主要的中樞神經系統適應症，潛在的候選藥物正在研發中。

預計癌症領域在預測期內將呈現最快的成長速度。患病率上升、死亡率高以及對有效治療的需求不斷成長預計將推動中樞神經系統治療市場的成長。根據美國國家癌症美國估計，2020 年美國新患者23,890 例，死亡病例 18,020 例。

製藥公司採用產品開拓、併購和聯盟等策略來加強其市場地位。例如，Biogen 與 Ionis Pharmaceuticals、Atalanta Therapeutics 和 Sangamo Therapeutics 達成協議，開發針對中樞神經系統各種疾病的新療法。同樣，2020 年 1 月，CNS Pharmaceuticals 與 MD 安德森癌症中心簽訂了授權合約，開發 WP1244，一種旨在穿越血腦障壁的 DNA粘合劑，以探索腦腫瘤的潛在治療方法。

中樞神經系統治療市場報告亮點

  • 由於阿茲海默症、帕金森氏症、多發性硬化症等盛行率不斷增加，神經退化性疾病預計在預測期內將以 11.5% 的複合年成長率成長最快。
  • 預計中樞神經系統癌症領域在預測期內將呈現最快的成長速度。對有效治療的需求不斷成長預計將推動這一領域的發展。
  • 由於治療率的提高和醫療基礎設施的改善，預計亞太地區在未來幾年將出現最快的成長。
  • 北美地區因其在該地區的高知名度和更好的贖回場景而在2024年佔據了大部分市場佔有率。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章中樞神經系統治療市場的變數、趨勢和範圍

  • 市場體系展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 營商環境分析
    • 產業分析-波特五力分析
    • PESTLE分析

第4章中樞神經系統治療市場：疾病業務分析

  • 2024年及2030年疾病市場佔有率
  • 疾病細分儀表板
  • 2018-2030 年按疾病分類的市場規模、預測與趨勢分析
  • 神經血管疾病
  • 中樞神經系統創傷
  • 心理健康
  • 神經退化性疾病
  • 感染疾病
  • 中樞神經系統癌症
  • 其他

第5章中樞神經系統治療市場：藥物類別的商業分析

  • 2024 年及 2030 年藥品類別市場佔有率
  • 藥品類別細分儀表板
  • 2018-2030 年按藥物類別分類的市場規模、預測與趨勢分析
  • 麻醉劑
  • 抗驚厥藥
  • 止吐藥
  • 中樞神經系統興奮劑
  • 止痛藥
  • 其他

第6章中樞神經系統治療市場：通路的業務分析

  • 2024 年及 2030 年分銷通路市場佔有率
  • 分銷通路細分儀表板
  • 2018-2030 年按分銷管道分類的市場規模、預測與趨勢分析
  • 醫院藥房
  • 零售藥房
  • 其他

第7章中樞神經系統治療市場：按疾病、藥物類別和分銷管道進行的區域估計和趨勢分析

  • 2024 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 2018-2030年市場規模、預測趨勢分析：
  • 北美洲
    • 按國家/地區分類，2018-2030
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 按國家/地區分類，2018-2030
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 丹麥
    • 瑞典
  • 亞太地區
    • 按國家/地區分類，2018-2030
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 按國家/地區分類，2018-2030
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 按國家/地區分類，2018-2030
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭格局

  • 參與企業概況
  • 公司市場分析
  • 公司分類
  • 策略規劃
  • 公司簡介
    • Biogen
    • Otsuka Pharmaceutical Co., Ltd.
    • Eli Lilly and Company
    • Merck &Co., Inc.
    • Astra Zeneca
    • Takeda Pharmaceutical Company Limited
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd
    • Johnson &Johnson Services, Inc.
    • Pfizer Inc.
Product Code: GVR-1-68038-516-8

Central Nervous System Therapeutic Market Growth & Trends:

The global central nervous system therapeutics market size is expected to reach USD 254.6 million by 2030, registering a CAGR of 10.4% from 2025 to 2030, according to a new report by Grand View Research, Inc. High unmet medical needs and government initiatives to reduce the disease burden are driving the market for central nervous system (CNS) therapeutic over the forecast period. According to WHO, the global economy loses due to depression and anxiety is more than USD 1 trillion per year and rising patient base of mental health globally is expected to increase the economy loses by USD 16 trillion in 2030.

The market holds strong future growth opportunities and major players are adopting different marketing strategies such as new product development, collaborations, geographic expansion, mergers and acquisitions, and new product approval, to strengthen their positions. In February 2020, Biogen announced the investment in Sangamo's zinc finger platform to develop therapies for Alzheimer's disease and other neurological diseases. Similarly, the company has an agreement with Ionis Pharmaceutical for the development of drug candidates applicable across a wide range of neurological diseases.

Presence of strong pipeline products by major pharmaceutical companies such as Biogen, H. Lundbeck A/S, Eli Lilly and Company, and others are expected to accelerate market growth over the forecast period. Besides, other pharmaceutical companies are also actively involved in the development of novel therapies and investing heavily to develop effective therapeutics for the treatment of CNS associated diseases.

Most of the late phase development drugs are for the treatment of neurodegenerative disorders such as Alzheimer's disease, multiple sclerosis, Parkinson's disease, and amyotrophic lateral sclerosis. The drug candidates such as aducanumab, brexpiprozole, evobrutinib, solanezumab are some of the potential drugs that could be commercialized in the next five to eight years for the treatment of various indication of neurodegenerative disorders. Apart from neurodegenerative diseases, migraine, schizophrenia, and epilepsy are the major CNS disease indications that have potential drug candidates in pipeline.

The cancer segment is expected to witness the fastest growth rate over the forecast period. Increasing prevalence, high mortality rate, and rising demand for effective treatment are expected to fuel the growth of the market for CNS therapeutic. According to National Cancer Institute estimates, the number of new cases of CNS cancers was 23,890 whereas the number of deaths was 18,020 in the U.S. in 2020.

Pharmaceutical companies are adopting strategies such as product development, merger and acquisition, and collaboration to strengthen their position in market. For instance, Biogen has signed agreements with Ionis Pharmaceuticals, Atalanta Therapeutics, and Sangamo Therapeutics to develop novel therapeutics for the treatment of different disease indications of the central nervous system. Similarly, in January 2020, the CNS Pharmaceuticals has entered into a licensing agreement with MD Anderson Cancer Center to investigate WP1244, a designed DNA-binding agent to cross the blood-brain barriers for the potential treatment of brain cancers.

Central Nervous System Therapeutic Market Report Highlights:

  • Neurodegenerative diseases are projected to witness the fastest growth with a CAGR of 11.5% over the forecast period, owing to the increasing prevalence of conditions such as Alzheimer's, Parkinson's, and multiple sclerosis.
  • The CNS cancer segment is expected to witness the fastest growth rate over the forecast period. Increasing demand for effective treatment is expected to drive the segment
  • In Asia Pacific, the market is estimated to witness the fastest growth over the coming years owing to the increase in treatment rate and betterment of healthcare infrastructure in the region
  • North America held a majority of share in 2024 due to high awareness level in the region and better reimbursement scenario

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Disease
    • 1.2.2. Drug Class
    • 1.2.3. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Central Nervous System Therapeutics Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Central Nervous System Therapeutics Market: Disease Business Analysis

  • 4.1. Disease Market Share, 2024 & 2030
  • 4.2. Disease Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Disease, 2018 to 2030 (USD Million)
  • 4.4. Neurovascular Diseases
    • 4.4.1. Neurovascular Diseases Market, 2018 - 2030 (USD Million)
  • 4.5. CNS Trauma
    • 4.5.1. CNS Trauma Market, 2018 - 2030 (USD Million)
  • 4.6. Mental Health
    • 4.6.1. Mental Health Market, 2018 - 2030 (USD Million)
    • 4.6.2. Anxiety Disorders
      • 4.6.2.1. Anxiety Disorders Market, 2018 - 2030 (USD Million)
    • 4.6.3. Epilepsy
      • 4.6.3.1. Epilepsy Market, 2018 - 2030 (USD Million)
    • 4.6.4. Mood Disorders
      • 4.6.4.1. Mood Disorders Market, 2018 - 2030 (USD Million)
    • 4.6.5. Psychotic Disorders
      • 4.6.5.1. Psychotic Disorders Market, 2018 - 2030 (USD Million)
    • 4.6.6. Others
      • 4.6.6.1. Others Market, 2018 - 2030 (USD Million)
  • 4.7. Neurodegenerative Diseases
    • 4.7.1. Neurodegenerative Diseases Market, 2018 - 2030 (USD Million)
    • 4.7.2. Alzheimer's Disease
      • 4.7.2.1. Alzheimer's Disease Market, 2018 - 2030 (USD Million)
    • 4.7.3. Parkinsosn's Disease
      • 4.7.3.1. Parkinsosn's Disease Market, 2018 - 2030 (USD Million)
    • 4.7.4. Multiple Sclerosis
      • 4.7.4.1. Multiple Sclerosis Market, 2018 - 2030 (USD Million)
    • 4.7.5. Huntington's Disease
      • 4.7.5.1. Huntington's Disease Market, 2018 - 2030 (USD Million)
    • 4.7.6. Amytrophic Lateral Sclerosis
      • 4.7.6.1. Amytrophic Lateral Sclerosis Market, 2018 - 2030 (USD Million)
    • 4.7.7. Others
      • 4.7.7.1. Others Market, 2018 - 2030 (USD Million)
  • 4.8. Infectious Diseases
    • 4.8.1. Infectious Diseases Market, 2018 - 2030 (USD Million)
  • 4.9. CNS Cancer
    • 4.9.1. CNS Cancer Market, 2018 - 2030 (USD Million)
  • 4.10. Others
    • 4.10.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Central Nervous System Therapeutics Market: Drug Class Business Analysis

  • 5.1. Drug Class Market Share, 2024 & 2030
  • 5.2. Drug Class Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
  • 5.4. Anesthetics
    • 5.4.1. Anesthetics Market, 2018 - 2030 (USD Million)
  • 5.5. Anticonvulsants
    • 5.5.1. Anticonvulsants Market, 2018 - 2030 (USD Million)
  • 5.6. Antiemetics
    • 5.6.1. Antiemetics Market, 2018 - 2030 (USD Million)
  • 5.7. CNS Stimulants
    • 5.7.1. CNS Stimulants Market, 2018 - 2030 (USD Million)
  • 5.8. Pain Relievers
    • 5.8.1. Pain Relievers Market, 2018 - 2030 (USD Million)
  • 5.9. Others
    • 5.9.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Central Nervous System Therapeutics Market: Distribution Channel Business Analysis

  • 6.1. Distribution Channel Market Share, 2024 & 2030
  • 6.2. Distribution Channel Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
  • 6.4. Hospital Pharmacies
    • 6.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
  • 6.5. Retail Pharmacies
    • 6.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Central Nervous System Therapeutics Market: Regional Estimates & Trend Analysis by Disease, Drug Class, Distribution Channel

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. North America Central Nervous System Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Regulatory Framework
      • 7.4.2.3. Competitive Insights
      • 7.4.2.4. U.S. Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Regulatory Framework
      • 7.4.3.3. Competitive Insights
      • 7.4.3.4. Canada Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Regulatory Framework
      • 7.4.4.3. Competitive Insights
      • 7.4.4.4. Mexico Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Central Nervous System Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Regulatory Framework
      • 7.5.2.3. Competitive Insights
      • 7.5.2.4. UK Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Regulatory Framework
      • 7.5.3.3. Competitive Insights
      • 7.5.3.4. Germany Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Regulatory Framework
      • 7.5.4.3. Competitive Insights
      • 7.5.4.4. France Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Regulatory Framework
      • 7.5.5.3. Competitive Insights
      • 7.5.5.4. Italy Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Regulatory Framework
      • 7.5.6.3. Competitive Insights
      • 7.5.6.4. Spain Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.7. Norway
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Regulatory Framework
      • 7.5.7.3. Competitive Insights
      • 7.5.7.4. Norway Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.8. Denmark
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Regulatory Framework
      • 7.5.8.3. Competitive Insights
      • 7.5.8.4. Denmark Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.9. Sweden
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Regulatory Framework
      • 7.5.9.3. Competitive Insights
      • 7.5.9.4. Sweden Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Central Nervous System Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Regulatory Framework
      • 7.6.2.3. Competitive Insights
      • 7.6.2.4. Japan Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Regulatory Framework
      • 7.6.3.3. Competitive Insights
      • 7.6.3.4. China Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Regulatory Framework
      • 7.6.4.3. Competitive Insights
      • 7.6.4.4. India Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. South Korea
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Regulatory Framework
      • 7.6.5.3. Competitive Insights
      • 7.6.5.4. South Korea Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.6. Australia
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Regulatory Framework
      • 7.6.6.3. Competitive Insights
      • 7.6.6.4. Australia Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Regulatory Framework
      • 7.6.7.3. Competitive Insights
      • 7.6.7.4. Thailand Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Central Nervous System Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Regulatory Framework
      • 7.7.2.3. Competitive Insights
      • 7.7.2.4. Brazil Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Regulatory Framework
      • 7.7.3.3. Competitive Insights
      • 7.7.3.4. Argentina Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.8. MEA
    • 7.8.1. MEA Central Nervous System Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Regulatory Framework
      • 7.8.2.3. Competitive Insights
      • 7.8.2.4. South Africa Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Regulatory Framework
      • 7.8.3.3. Competitive Insights
      • 7.8.3.4. Saudi Arabia Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Regulatory Framework
      • 7.8.4.3. Competitive Insights
      • 7.8.4.4. UAE Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Regulatory Framework
      • 7.8.5.3. Competitive Insights
      • 7.8.5.4. Kuwait Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Biogen
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Otsuka Pharmaceutical Co., Ltd.
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Eli Lilly and Company
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Merck & Co., Inc.
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Astra Zeneca
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Takeda Pharmaceutical Company Limited
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Novartis AG
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Teva Pharmaceutical Industries Ltd
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Johnson & Johnson Services, Inc.
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Pfizer Inc.
      • 8.5.10.1. Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. Global central nervous system therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 4. Global central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 5. Global central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 6. Global central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 7. North America central nervous system therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 8. North America central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 9. North America central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 10. North America central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 11. U.S. central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 12. U.S. central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 13. U.S. Central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 14. Canada central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 15. Canada central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 16. Canada central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 17. Mexico central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 18. Mexico central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 19. Mexico central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 20. Europe central nervous system therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 21. Europe central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 22. Europe central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 23. Europe central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 24. UK central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 25. UK central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 26. UK Central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 27. Germany central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 28. Germany central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 29. Germany central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 30. France central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 31. France central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 32. France Central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 33. Italy central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 34. Italy central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 35. Italy central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 36. Spain central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 37. Spain central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 38. Spain central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 39. Norway central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 40. Norway central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 41. Norway Central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 42. Denmark central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 43. Denmark central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 44. Denmark central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 45. Sweden central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 46. Sweden central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 47. Sweden central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 48. Asia Pacific central nervous system therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 49. Asia Pacific central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 50. Asia Pacific central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 51. Asia Pacific central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 52. Japan central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 53. Japan central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 54. Japan central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 55. China central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 56. China central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 57. China central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 58. India central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 59. India central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 60. India central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 61. Australia central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 62. Australia central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 63. Australia central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 64. South Korea central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 65. South Korea central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 66. South Korea central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 67. Thailand central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 68. Thailand central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 69. Thailand central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 70. Latin America central nervous system therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 71. Latin America central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 72. Latin America central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 73. Latin America central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 74. Brazil central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 75. Brazil central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 76. Brazil central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 77. Argentina central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 78. Argentina central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 79. Argentina central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 80. Middle East & Africa Central nervous system therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 81. Middle East & Africa central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 82. Middle East & Africa central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 83. Middle East & Africa central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 84. South Africa central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 85. South Africa central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 86. South Africa central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 87. Saudi Arabia central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 88. Saudi Arabia central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 89. Saudi Arabia central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 90. UAE central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 91. UAE central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 92. UAE central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 93. Kuwait central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 94. Kuwait central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 95. Kuwait central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Central nervous system therapeutics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Disease and drug class (USD Million)
  • Fig. 10 Distribution channel outlook
  • Fig. 11 Competitive landscape
  • Fig. 12 Central nervous system therapeutics market dynamics
  • Fig. 13 Central nervous system therapeutics market: Porter's five forces analysis
  • Fig. 14 Central nervous system therapeutics market: PESTLE analysis
  • Fig. 15 Central nervous system therapeutics market Disease segment dashboard
  • Fig. 16 Central nervous system therapeutics market: Disease market share analysis, 2024 & 2030
  • Fig. 17 Neurovascular diseases market, 2018 - 2030 (USD Million)
  • Fig. 18 CNS trauma market, 2018 - 2030 (USD Million)
  • Fig. 19 Mental health market, 2018 - 2030 (USD Million)
  • Fig. 20 Anxiety disorders market, 2018 - 2030 (USD Million)
  • Fig. 21 Epilepsy market, 2018 - 2030 (USD Million)
  • Fig. 22 Mood disorders market, 2018 - 2030 (USD Million)
  • Fig. 23 Psychotic disorders market, 2018 - 2030 (USD Million)
  • Fig. 24 Others market, 2018 - 2030 (USD Million)
  • Fig. 25 Neurodegenerative diseases market, 2018 - 2030 (USD Million)
  • Fig. 26 Alzheimer's disease market, 2018 - 2030 (USD Million)
  • Fig. 27 Parkinsosn's disease market, 2018 - 2030 (USD Million)
  • Fig. 28 Multiple sclerosis market, 2018 - 2030 (USD Million)
  • Fig. 29 Huntington's disease market, 2018 - 2030 (USD Million)
  • Fig. 30 Amytrophic lateral sclerosis market, 2018 - 2030 (USD Million)
  • Fig. 31 Others market, 2018 - 2030 (USD Million)
  • Fig. 32 Infectious diseases market, 2018 - 2030 (USD Million)
  • Fig. 33 CNS cancer market, 2018 - 2030 (USD Million)
  • Fig. 34 Others market, 2018 - 2030 (USD Million)
  • Fig. 35 Central nervous system therapeutics market: Drug class segment dashboard
  • Fig. 36 Central nervous system therapeutics market: Drug class market share analysis, 2024 & 2030
  • Fig. 37 Anesthetics market, 2018 - 2030 (USD Million)
  • Fig. 38 Anticonvulsants market, 2018 - 2030 (USD Million)
  • Fig. 39 Antiemetics market, 2018 - 2030 (USD Million)
  • Fig. 40 CNS stimulants market, 2018 - 2030 (USD Million)
  • Fig. 41 Pain relievers market, 2018 - 2030 (USD Million)
  • Fig. 42 Others market, 2018 - 2030 (USD Million)
  • Fig. 43 Central nervous system therapeutics market: Distribution channel segment dashboard
  • Fig. 44 Central nervous system therapeutics market: Distribution channel market share analysis, 2024 & 2030
  • Fig. 45 Hospital pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 46 Retail pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 47 Others market, 2018 - 2030 (USD Million)
  • Fig. 48 Central nervous system therapeutics market revenue, by region
  • Fig. 49 Regional marketplace: Key takeaways
  • Fig. 50 Regional marketplace: Key takeaways
  • Fig. 51 North America central nervous system therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 52 U.S. country dynamics
  • Fig. 53 U.S. central nervous system therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 54 Canada country dynamics
  • Fig. 55 Canada central nervous system therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 56 Mexico country dynamics
  • Fig. 57 Mexico central nervous system therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 58 Europe central nervous system therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 59 UK country dynamics
  • Fig. 60 UK central nervous system therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 61 Germany country dynamics
  • Fig. 62 Germany central nervous system therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 63 France country dynamics
  • Fig. 64 France central nervous system therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 65 Italy country dynamics
  • Fig. 66 Italy central nervous system therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 67 Spain country dynamics
  • Fig. 68 Spain central nervous system therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 69 Norway country dynamics
  • Fig. 70 Norway central nervous system therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 71 Sweden country dynamics
  • Fig. 72 Sweden central nervous system therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 73 Denmark country dynamics
  • Fig. 74 Denmark central nervous system therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 75 Asia Pacific central nervous system therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 76 Japan country dynamics
  • Fig. 77 Japan central nervous system therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 78 China country dynamics
  • Fig. 79 China central nervous system therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 80 India country dynamics
  • Fig. 81 India central nervous system therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 82 Australia country dynamics
  • Fig. 83 Australia central nervous system therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 84 South Korea country dynamics
  • Fig. 85 South Korea central nervous system therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 86 Thailand country dynamics
  • Fig. 87 Thailand central nervous system therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 88 Latin America central nervous system therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 89 Brazil country dynamics
  • Fig. 90 Brazil central nervous system therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 91 Argentina country dynamics
  • Fig. 92 Argentina central nervous system therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 93 MEA central nervous system therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 94 South Africa country dynamics
  • Fig. 95 South Africa central nervous system therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 96 Saudi Arabia country dynamics
  • Fig. 97 Saudi Arabia central nervous system therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 98 UAE country dynamics
  • Fig. 99 UAE central nervous system therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 100 Kuwait country dynamics
  • Fig. 101 Kuwait central nervous system therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 102 Company categorization
  • Fig. 103 Company market position analysis
  • Fig. 104 Strategic framework